The FAERS database supports post-market surveillance by collecting which of the following?

The FAERS database supports post-market surveillance by collecting which of the following?

• A. Adverse events and product recalls only
• B. Medication errors and consumer complaints
• C. Adverse events, medication errors, and product quality complaints
• D. Adverse events only

Answer: (C)

Post-market safety surveillance relies on collecting diverse safety data after a drug enters the market to detect signals early. The FAERS database is designed to capture three main types of reports: adverse events (unfavorable health outcomes in patients taking the drug), medication errors (mistakes in prescribing, dispensing, or administering that can cause harm), and product quality complaints (issues related to the drug’s quality, stability, packaging, or manufacturing). Having all three categories lets regulators see safety problems from different angles—clinical harm, processing mistakes, and manufacturing/quality issues—so signals aren’t missed. The other options fall short because they omit one or more of these data types. Limiting to adverse events misses potential harm from medication errors and quality problems. Focusing on recalls alone doesn’t account for the ongoing reports of adverse events or product quality issues, and emphasizing consumer complaints without the formal categories of adverse events and product quality would overlook important data.

Post-market safety surveillance relies on collecting diverse safety data after a drug enters the market to detect signals early. The FAERS database is designed to capture three main types of reports: adverse events (unfavorable health outcomes in patients taking the drug), medication errors (mistakes in prescribing, dispensing, or administering that can cause harm), and product quality complaints (issues related to the drug’s quality, stability, packaging, or manufacturing). Having all three categories lets regulators see safety problems from different angles—clinical harm, processing mistakes, and manufacturing/quality issues—so signals aren’t missed.

The other options fall short because they omit one or more of these data types. Limiting to adverse events misses potential harm from medication errors and quality problems. Focusing on recalls alone doesn’t account for the ongoing reports of adverse events or product quality issues, and emphasizing consumer complaints without the formal categories of adverse events and product quality would overlook important data.